429 related articles for article (PubMed ID: 28049946)
21. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
22. Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid.
Grymowicz M; Czajkowski K; Smolarczyk R
Scand J Gastroenterol; 2016 Jan; 51(1):78-85. PubMed ID: 26152830
[TBL] [Abstract][Full Text] [Related]
23. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
24. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
25. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid.
Brites D
Ann Hepatol; 2002; 1(1):20-8. PubMed ID: 15114292
[TBL] [Abstract][Full Text] [Related]
26. Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells.
Alaca N; Özbeyli D; Uslu S; Şahin HH; Yiğittürk G; Kurtel H; Öktem G; Çağlayan Yeğen B
Turk J Gastroenterol; 2017 Nov; 28(6):476-484. PubMed ID: 29086715
[TBL] [Abstract][Full Text] [Related]
27. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
28. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
29. Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study.
Manna LB; Ovadia C; Lövgren-Sandblom A; Chambers J; Begum S; Seed P; Walker I; Chappell LC; Marschall HU; Williamson C
BJOG; 2019 Dec; 126(13):1633-1640. PubMed ID: 31483939
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.
Ishizaki K; Iwaki T; Kinoshita S; Koyama M; Fukunari A; Tanaka H; Tsurufuji M; Sakata K; Maeda Y; Imada T; Chiba K
Eur J Pharmacol; 2008 Jan; 578(1):57-64. PubMed ID: 17888421
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
32. Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice.
Zhang L; Su H; Li Y; Fan Y; Wang Q; Jiang J; Hu Y; Chen G; Tan B; Qiu F
Toxicol Appl Pharmacol; 2018 Mar; 342():69-78. PubMed ID: 29407775
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
34. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
35. [Ursodeoxycholic acid: history and clinical implications].
Beuers U; Trampert DC
Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.
Zapata R; Sandoval L; Palma J; Hernández I; Ribalta J; Reyes H; Sedano M; Tohá D; Silva JJ
Liver Int; 2005 Jun; 25(3):548-54. PubMed ID: 15910492
[TBL] [Abstract][Full Text] [Related]
37. Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment.
Rodrigues CM; Marín JJ; Brites D
Gut; 1999 Sep; 45(3):446-52. PubMed ID: 10446117
[TBL] [Abstract][Full Text] [Related]
38. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
[TBL] [Abstract][Full Text] [Related]
39. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
40. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
